Beam Therapeutics (NASDAQ:BEAM – Get Free Report) issued its quarterly earnings results on Tuesday. Beam Therapeutics had a negative return on equity of 29.00% and a negative net margin of 39.66%.The firm’s quarterly revenue was down 94.2% on a year-over-year basis. Beam Therapeutics Price PerformanceBEAM opened at $27.46 on Tuesday. Beam Therapeutics has a fifty-two week low of $15.60 and a fifty-two week high of $38.26. New York State Common Retirement Fund increased its holdings in shares of Beam Therapeutics by 17.7% in the 2nd quarter.